Thought Leader Liaison - Northeast

The role

The Director, Thought Leader Liaison develops and executes a strategic engagement model with external thought leaders in rare neuromuscular diseases. This role builds relationships with neuromuscular experts and translates insights into commercial strategy.

What you will do

• Develop and execute a thought leader engagement strategy focused on rare neuromuscular diseases.
• Identify, profile, and prioritize national and regional neuromuscular thought leaders.
• Build and sustain long-term relationships with clinicians and experts.
• Capture and translate insights from thought leaders into actionable recommendations.
• Provide strategic input into positioning, messaging, and tactical planning.
• Monitor KOL insights related to market dynamics and competitive intelligence.
• Lead commercial engagement strategy for neuromuscular congresses.
• Design and execute advisory boards, speaker programs, and peer-to-peer educational initiatives.
• Identify and recruit KOLs for content development and marketing projects.
• Collaborate with Sales, Marketing, Medical Affairs, Market Access, Training, Legal, and Compliance.

Required qualifications

• Bachelor's degree
• 10+ years of experience in biotechnology or pharmaceutical commercial roles
• Demonstrated experience engaging neuromuscular or rare disease thought leaders in a commercial context
• Strong understanding of the rare disease commercialization landscape
• Ability to translate complex scientific and clinical insights into commercial strategies
• Excellent interpersonal, oral, and written communication skills
• Strong cross-functional collaboration skills
• Experience operating in matrixed organizations
• Demonstrated commitment to ethical, compliant engagement practices
• Proven ability to manage a large geographical territory
• Domestic travel up to 80% is required

Nice to have

• Advanced degree
• Experience in rare disease or specialty markets

About the company

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for other diseases.